Qosa et al. tested a set of tyrosine kinase inhibitors (TKIs) for UGT1A1 inhibition [75], and they found that Cmax/IC50 ratios greater than 1 were associated with hyperbilirubinemia: erlotinib, nilotinib, regorafenib, pazopanib, sorafenib and vemurafenib with Cmax/IC50 > 1 all had high Empirical Bayesian Geometric Mean (EBGM) scores for this condition (Table 3). The gene discussed is UGT1A1; the disease is Hyperbilirubinemia.